Cargando…

Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland

BACKGROUND: This study aimed to undertake an analysis of ten years of real-world evidence (RWE) on overall survival (OS) following treatment of advanced gastrointestinal stromal tumor (GIST) with imatinib, sunitinib, and sorafenib using data from the Polish National Health Fund. MATERIAL/METHODS: Da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brzozowska, Melania, Wierzba, Waldemar, Szafraniec-Buryło, Sylwia, Czech, Marcin, Połowinczak-Przybyłek, Joanna, Potemski, Piotr, Śliwczyński, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543874/ https://www.ncbi.nlm.nih.gov/pubmed/31121600 http://dx.doi.org/10.12659/MSM.914517

Ejemplares similares

Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
por: Brzozowska, Melania, et al.
Publicado: (2019)

Epidemiology of multiple myeloma in Poland in the years 2008–2017
por: Waszczuk-Gajda, Anna, et al.
Publicado: (2020)

Analysis of the survival of patients receiving systemic treatment for melanoma of the skin: a retrospective population study with patients treated in Poland in 2011–2015
por: Brzozowska, Melania, et al.
Publicado: (2019)

Syphilis in Poland is on the rise and underreported
por: Teter, Zbigniew, et al.
Publicado: (2019)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Trends in psoriatic arthritis epidemiology in Poland
por: Tłustochowicz, Małgorzata, et al.
Publicado: (2020)

Evaluation of the incidence of aortic aneurysms in patients with and without diabetes in Poland in 2012 based on the database of the National Health Fund
por: Wierzba, Waldemar, et al.
Publicado: (2017)

Comparison of the incidence of new malignancies in diabetic patients in urban and rural populations in Poland in the years 2008–2014 based on the database of the National Health Fund
por: Wierzba, Waldemar, et al.
Publicado: (2017)

Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015
por: Śliwczyński, Andrzej, et al.
Publicado: (2017)

Cost-effectiveness analysis of COVID-19 vaccination in Poland
por: Orlewska, Katarzyna, et al.
Publicado: (2021)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Epidemiology and direct costs of atopic dermatitis in Poland based on the National Health Fund register (2008–2017)
por: Raciborski, Filip, et al.
Publicado: (2018)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Tamoxifen-induced acute pancreatitis – a case report
por: Czyżykowski, Rafał, et al.
Publicado: (2014)

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
por: Rutkowski, Piotr, et al.
Publicado: (2012)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Analysis of National Health and Insurance Registers for All-Cause Mortality in Patients with Heart Failure with and without Diabetes Mellitus in Poland in 2012
por: Wierzba, Waldemar, et al.
Publicado: (2019)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Diabetes mellitus and congestive heart failure: the prevalence of congestive heart failure in patients with and without diabetes in Poland
por: Wierzba, Waldemar, et al.
Publicado: (2018)

Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review
por: Tan, Siyuan, et al.
Publicado: (2018)

Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience
por: Straś, Wojciech, et al.
Publicado: (2021)

Recommendations for the Development of Telemedicine in Poland Based on the Analysis of Barriers and Selected Telemedicine Solutions
por: Furlepa, Kamila, et al.
Publicado: (2022)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
por: Raciborski, Filip, et al.
Publicado: (2016)

Regional differences in the frequency of diabetes occurrence and its treatment costs during the years 2008–2013, based on the NFZ (National Health Fund) database
por: Śliwczyński, Andrzej M., et al.
Publicado: (2016)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

The association of diabetes with all-cause mortality in patients with end-stage renal disease compared to the general population in Poland – a comparative analysis
por: Wierzba, Waldemar, et al.
Publicado: (2020)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008–2012
por: Śliwczyński, Andrzej, et al.
Publicado: (2015)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Sorafenib and sunitinib: A dermatologist's perspective
por: Pragasam, Vijendran, et al.
Publicado: (2014)

Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
por: Vetto, John T
Publicado: (2009)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
por: Ghias, Adnan Asif Parvez, et al.
Publicado: (2018)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_scvnjkhl44oqd8em1kp3ekjs9u